• Prevent rabies infection

Twinrab 600IU injection contains two antibodies: docaravimab and miromavimab. These antibodies bind to the rabies virus and prevent it from entering and infecting nerve cells and other cells in the body. This interruption of the virus's ability to replicate and spread within the body is crucial for halting the progression of rabies infection.

Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional or vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with twinrab 600IU injection and cause undesirable side effects.

• Keep docaravimab + miromavimab Injection out of sight and reach of children.
• Store between 2°C and 8°C.

Twinrab 600IU injection is given only in a hospital set up by a trained healthcare provider. It will be given to you as an injection into your muscle (intramuscularly) for adults in the arm and children in the thigh. Your doctor will decide your most apt dosage based on age, body weight, and physical circumstances. 

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them.

Serious

• Allergic Reactions

Common

• Injection site pain
• Irritability
• Headache, dizziness
• Nausea

For those prescribed twinrab 600IU injection, it is crucial to prioritize safety through open communication with your healthcare provider. Adhering strictly to the prescribed dosage and schedule is paramount. If this injection is combined with a rabies vaccine, ensure compliance with the recommended vaccination schedule. Attend all scheduled follow-up appointments for proper monitoring. 

Familiarize yourself with the signs of severe reactions and seek immediate medical attention if necessary. Communicate promptly with your healthcare provider regarding any changes in your health status. If you are pregnant or planning to breastfeed, discuss your plans with your healthcare provider. Always seek personalized advice from healthcare professionals to ensure your safety during treatment.

1. Zydus; the U.S. Food And Drug Administration (FDA) [Accessed on 14/08/202] https://www.fda.gov/media/106517/download 
2. Kevinkumar Kansagra et al. A Phase 3, Randomised, Open-Label, Non-inferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG); Clinical Infectious Diseases; Published on 17/06/2020; Accessed on 14/08/2021; https://pubmed.ncbi.nlm.nih.gov/32556113/ 
3. De Melo GD et al., A combination of two human monoclonal antibodies cures symptomatic rabies; EMBO Mol Med; Published on 06/11/2020; Accessed on 13/11/2023 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7645379/ 
4. Anti-rabies virus monoclonal antibodies, World Health Organisation (WHO), https://list.essentialmeds.org/recommendations/1220/print?format=pdf